Valuation: MannKind Corporation

Capitalization 1.82B 1.55B 1.45B 1.37B 2.51B 165B 2.75B 16.94B 6.57B 77.88B 6.84B 6.7B 284B P/E ratio 2025 *
50.1x
P/E ratio 2026 * 52.2x
Enterprise value 1.82B 1.55B 1.45B 1.37B 2.51B 165B 2.75B 16.94B 6.57B 77.88B 6.84B 6.7B 284B EV / Sales 2025 *
5.27x
EV / Sales 2026 * 4.19x
Free-Float
98.17%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: MannKind Corporation

1 day+2.24%
1 week+4.58%
Current month+11.03%
1 month+17.16%
3 months+6.64%
6 months+60.11%
Current year-7.62%
More quotes
1 week 5.58
Extreme 5.585
6.01
1 month 4.93
Extreme 4.93
6.01
Current year 3.38
Extreme 3.3812
6.68
1 year 3.38
Extreme 3.3812
7.07
3 years 3.17
Extreme 3.17
7.63
5 years 2.49
Extreme 2.49
7.63
10 years 0.67
Extreme 0.6662
11.2
More quotes
Manager TitleAgeSince
Chief Executive Officer 48 24/05/2017
Director of Finance/CFO 50 21/04/2024
Chief Tech/Sci/R&D Officer - 28/09/2025
Director TitleAgeSince
Director/Board Member 81 30/09/2003
Director/Board Member 81 30/11/2003
Chairman 69 08/12/2020
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+2.24%+4.58%-9.17%+21.47% 1.82B
-0.48%-2.31%+29.68%+105.96% 54.11B
+0.91%-3.43%+175.04%+885.05% 42.02B
+0.70%+4.04%+66.46%+19.35% 39.6B
-1.24%-1.50%-21.24%-46.81% 22.8B
-1.52%-0.84%+40.08%-36.97% 19.5B
0.00%+2.64%+88.09%-34.80% 17.76B
+6.05%+0.32%+95.60%+196.08% 14.73B
-2.33%-4.04%-1.46%+349.36% 13.55B
+5.03%-4.65%+133.80% - 13.14B
Average +0.94%-0.65%+59.69%+162.08% 23.9B
Weighted average by Cap. +0.46%-1.12%+69.38%+216.67%
See all sector performances

Financials

2025 *2026 *
Net sales 346M 295M 275M 259M 477M 31.33B 521M 3.21B 1.25B 14.77B 1.3B 1.27B 53.88B 435M 370M 346M 326M 599M 39.39B 655M 4.04B 1.57B 18.57B 1.63B 1.6B 67.74B
Net income 37.42M 31.88M 29.78M 28.02M 51.58M 3.39B 56.35M 348M 135M 1.6B 140M 137M 5.83B 34.42M 29.33M 27.39M 25.77M 47.45M 3.12B 51.84M 320M 124M 1.47B 129M 126M 5.36B
Net Debt - -
More financial data * Estimated data
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
405
More about the company
Date Price Change Volume
12/12/25 5.940 $ +2.24% 3,389,533
11/12/25 5.810 $ -0.51% 3,697,705
10/12/25 5.840 $ +1.21% 3,332,532
09/12/25 5.770 $ +2.49% 4,410,815
08/12/25 5.630 $ -0.88% 2,547,585

Delayed Quote Nasdaq, December 12, 2025 at 09:00 pm

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.940USD
Average target price
9.611USD
Spread / Average Target
+61.80%
Consensus

Quarterly revenue - Rate of surprise